Kjell A.
- Country
- Norway
- Department
- National Neuromuscular Centre
Research Overview
- Open-Label Extension Study Assessing Long-Term Safety and Efficacy of Oral Ribitol (BBP-418) in Adults with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ribitol (BBP-418) in Limb Girdle Muscular Dystrophy 2I/R9
Data & Insights
Has run more than one trial at 5 of 6 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the study of Limb Girdle Muscular Dystrophy, with particular emphasis on the LGMD2I/R9 variant. Their research focuses on evaluating therapeutic interventions for this rare genetic condition that affects muscle strength and mobility.
- Muscular Dystrophy Treatment
- Genetic Muscle Disorders
- Neuromuscular Disease Management
The investigator's work encompasses clinical evaluation of novel therapeutic compounds for treating muscular dystrophy disorders.
Rare Disease Research
The investigator conducts research in rare genetic disorders, specifically focusing on innovative treatment approaches for muscle-wasting conditions. Their expertise extends to evaluating therapeutic efficacy in genetic muscle disorders.
- Rare Disease Therapeutics
- Clinical Efficacy Assessment
- Patient Safety Monitoring
Their work contributes to advancing treatment options for patients with rare muscular conditions.
Therapeutic Development
The investigator's research involves studying novel therapeutic compounds for neuromuscular conditions. They focus on evaluating treatments that target specific genetic muscle disorders.
- Drug Safety Assessment
- Clinical Outcomes Research
- Treatment Efficacy Studies
Their expertise includes conducting clinical evaluations of emerging therapies for muscular dystrophy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.